Prevalence and clinical outcomes of respiratory syncytial virus, COVID-19, and influenza among older hospitalized adults: the EVERY prospective cohort study
Clinical Microbiology and Infection · 2026-05 · 32 (5) · 845-852
DOI: 10.1016/j.cmi.2026.01.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026-05. Verfasst von Takeshi Morimoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Science, Hyogo Medical University, Nishinomiya, Japan. Electronic address: morimoto@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals.
Abstract (Originalsprache)
OBJECTIVES: The impact of respiratory syncytial virus (RSV) among older adults hospitalized for acute respiratory symptoms was uncertain. We compared the prevalence and clinical outcomes of RSV with those of COVID-19 and influenza in older adults hospitalized for acute respiratory symptoms. METHODS: We conducted a multicentre prospective cohort study at three community hospitals, which enrolled emergently hospitalized adults aged ≥50 years with acute respiratory symptoms or signs from July 1, 2023, to December 31, 2024. RSV, COVID-19, and influenza A/B were measured using the FilmArray Respiratory panel 2.1 on a nasopharyngeal swab. The primary outcomes were lower respiratory tract infections (LRTIs), defined as presence of ≥2 lower respiratory symptoms/signs for at least 24 hours, including ≥1 lower respiratory sign or presence of ≥3 lower respiratory symptoms for at least 24 hours; modified LRTIs, incorporating chest radiography or computed tomography; and the 30-day all-cause mortality. RESULTS: During the 18-month study period, 3067 patients were included, with a mean age of 81 years (standard deviation: 11), and 55% of whom were male. Comorbidities included chronic pulmonary diseases (28%), chronic heart failure (32%), and diabetes (30%). The vaccination rates for RSV, COVID-19, and influenza were 0%, 62.3%, and 37.9%, respectively. The prevalence of RSV, COVID-19, and influenza A/B was 1.6%, 18.0%, and 2.3%, respectively. The rates of LRTIs were 87.8% (RSV), 82.8% (COVID-19), and 88.4% (influenza A/B). The rates of modified LRTIs exhibited a marginal increase. The 30-day mortality was highest among patients with RSV (14.3%) compared with those with COVID-19 (8.4%) and influenza A/B (2.9%) (p = 0.02). The adjusted odds ratios (95% confidence intervals) of 30-day mortality with RSV and COVID-19 relative to influenza A/B were 5.2 (1.2-36.7) and 2.9 (0.83-17.9), respectively. CONCLUSIONS: RSV should be recognized as a risk factor for mortality among older adults emergently hospitalized for acute respiratory symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Data Science, Hyogo Medical University, Nishinomiya, Japan. Electronic address: morimoto@kuhp.kyoto-u.ac.jp.
- Department of Data Science, Hyogo Medical University, Nishinomiya, Japan; Department of General Medicine, Nara City Hospital, Nara, Japan.
- Department of Infectious Diseases, Rakuwakai Otowa Hospital, Kyoto, Japan.
- Department of Data Science, Hyogo Medical University, Nishinomiya, Japan.
- Department of Data Science, Hyogo Medical University, Nishinomiya, Japan; Department of General Internal Medicine, Kobe City Medical Center West Hospital, Kobe, Japan.
- Department of Infectious Diseases, Shimane Prefectural Central Hospital, Izumo, Japan.
Förderung
- GlaxoSmithKline Biologicals
Zitieren
APA
Morimoto, T., Morikawa, T., Imura, H., Nezu, M., Hamazaki, K., Sakuma, M., & Nakamura, T. (2026). Prevalence and clinical outcomes of respiratory syncytial virus, COVID-19, and influenza among older hospitalized adults: the EVERY prospective cohort study. Clinical Microbiology and Infection, 32(5), 845-852. https://doi.org/10.1016/j.cmi.2026.01.002
Vancouver
Morimoto T, Morikawa T, Imura H, Nezu M, Hamazaki K, Sakuma M, et al. Prevalence and clinical outcomes of respiratory syncytial virus, COVID-19, and influenza among older hospitalized adults: the EVERY prospective cohort study. Clinical Microbiology and Infection. 2026;32(5):845-852. doi:10.1016/j.cmi.2026.01.002
BibTeX
@article{Morimoto2026,
author = {Morimoto, Takeshi and Morikawa, Toru and Imura, Haruki and Nezu, Mari and Hamazaki, Kenya and Sakuma, Mio and Nakamura, Tsukasa},
title = {Prevalence and clinical outcomes of respiratory syncytial virus, COVID-19, and influenza among older hospitalized adults: the EVERY prospective cohort study},
journal = {Clinical Microbiology and Infection},
year = {2026},
volume = {32},
number = {5},
pages = {845--852},
doi = {10.1016/j.cmi.2026.01.002}
}
EUVIMED